FATE Crosses Above Average Analyst Target
September 29, 2020 at 08:21 AM EDT
In recent trading, shares of Fate Therapeutics Inc (FATE) have crossed above the average analyst 12-month target price of $39.43, changing hands for $40.50/share. When a stock reaches the target an analyst has set, the analyst logically has two ways to react: downgrade on valuation, or, re-adjust their target price to a higher level..